title: Pharmacological thromboembolic prophylaxis for medical patients in a tertiary care, teaching community hospital: room for improvement.
abstract: Venous Thrombembolism (VTE) is a potentially lethal complication in hospitalized patients. Studies indicate that pharmacological prophylaxis may reduce the incidence of VTE. However, the use of VTE prophylaxis remains unclear. We aimed to retrospectively assess whether medically ill hospitalized patients with established risk factors receive pharmacological VTE prophylaxis in our 912-bed community-based tertiary care teaching hospital between 1997 and 2003. We randomly selected a sample of 350 medically ill (non surgical) hospitalized patients with risk factors for VTE. A total of 164 of 321 patients (51.1%) received pharmacological VTE prophylaxis. Patients with a platelet count of greater than or equal to 278 K/cu mm, a weight of 146 to 184 lbs, or a weight > or = 185 lbs were found more likely to receive prophylaxis. Patients with cancer as well as other diagnoses (compared to MI patients) were less likely to receive prophylaxis. We conclude that there continues to be a significant underutilization of VTE prophylaxis in this patient population. Strategies for identifying patients at risk for VTE and implementing appropriate protocols to ensure that these patients receive prophylaxis are necessary.
authors.affiliation: CAMC Health Education and Research Institute, West Virginia University School of Medicine, Charleston Division, USA.
authors.forename: Steven J
authors.initials: SJ
authors.lastname: Jubelirer
authors.forename: Bernardo j
authors.initials: Bj
authors.lastname: Reyes
authors.forename: Mike
authors.initials: M
authors.lastname: Broce
authors.forename: Abdul-Karim
authors.initials: AK
authors.lastname: Elhabyan
authors.forename: Kathleen
authors.initials: K
authors.lastname: Mimnagh
authors.forename: J Gregory
authors.initials: JG
authors.lastname: Rosencrance
authors.forename: Tanya
authors.initials: T
authors.lastname: Warwick
authors.forename: Mary K
authors.initials: MK
authors.lastname: Emmett
mesh_terms: D000925:Anticoagulants / Q000627:therapeutic use; D017984:Enoxaparin / Q000627:therapeutic use; D005260:Female; D006764:Hospitals, Community; D006784:Hospitals, Teaching; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000150:complications; D012189:Retrospective Studies; D012307:Risk Factors; D013923:Thromboembolism / Q000209:etiology / Q000517:prevention & control*; D019851:Thrombophilia / Q000150:complications; D020246:Venous Thrombosis / Q000209:etiology / Q000517:prevention & control*
chemical_list: D000925:Anticoagulants; D017984:Enoxaparin